Open AccessExtreme Prostate‐Specific Antigen Response to Infusional 5‐Flourouracil in Castrate‐Resistant Prostate Cancer
Author(s) -
Manogue Charlotte,
Ledet Elisa,
Guddati A. Kumar,
Lewis Brian,
Sartor Oliver
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0450
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , prostate , oncology , prostate specific antigen , taxane , antigen , cancer , urology , immunology , breast cancer
Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous‐infusion 5‐fluorouracil (5‐FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate‐resistant prostate cancer. Baseline prostate‐specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5‐FU therapy. We hypothesized that prostate‐specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.